Authorized purpose: Brainomix 360 e-CTA analyzes adult CTA brain DICOM for vessel visualization and post-processing, including MCA vessel-density asymmetry, contrast/phase context, overlays, and MIP views, for trained clinical review; it is not for mobile diagnosis and its vessel-density asymmetry ratio is limited to the MCA region.
Clinical role
CTA visualization and analysis support for reviewing hemispheric vessel-density differences, contrast intensity, estimated phase, and registered overlays; the results support but do not replace trained clinical interpretation.
Images and patients
CT/CTA · Brain
Key limitation
Keep in mind: The vessel-density asymmetry ratio applies only to the MCA region. Brainomix 360 e-CTA is not intended for mobile diagnostic use. Email previews are compressed and for informational notification only; clinicians must view non-compressed images on a diagnostic viewer and complete appropriate patient evaluation before care-related decisions.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Brainomix 360 e-CTA analyzes adult CTA brain DICOM for vessel visualization and post-processing, including MCA vessel-density asymmetry, contrast/phase context, overlays, and MIP views, for trained clinical review; it is not for mobile diagnosis and its vessel-density asymmetry ratio is limited to the MCA region.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain Input: Brain CT angiography images acquired through DICOM-compliant imaging devices and transferred from a PACS or other DICOM-compliant device.
Who uses it?Intended users: Trained professionals, including physicians and medical technicians, with interpretation by a trained clinician responsible for care decisions.
What does the software produce?Output: Visualization and post-processing outputs including registration, MIP views, a colored overlay of the MCA hemisphere with lower vessel density, relative vessel-density asymmetry, contrast-intensity measurements, and estimated phase; results can be sent to PACS or viewed through a hospital-network web interface, while email previews are compressed informational attachments.
What is its most important limitation?Key limitation: The vessel-density asymmetry ratio applies only to the MCA region. Brainomix 360 e-CTA is not intended for mobile diagnostic use. Email previews are compressed and for informational notification only; clinicians must view non-compressed images on a diagnostic viewer and complete appropriate patient evaluation before care-related decisions.
Clinical takeaway. Clinical role: Brainomix 360 e-CTA analyzes adult CTA brain DICOM for vessel visualization and post-processing, including MCA vessel-density asymmetry, contrast/phase context, overlays, and MIP views, for trained clinical review; it is not for mobile diagnosis and its vessel-density asymmetry ratio is limited to the MCA region.
Evidence takeaway. Evidence from the reviewed source record: K242123 FDA evidence is a retrospective standalone manufacturer-submitted validation of vessel delineation and parenchyma masking on 308 brain CTA scans; all cases were processed successfully. No independent paper or trial was promoted in this timeboxed review.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Brainomix 360 e-CTA analyzes adult CTA brain DICOM for vessel visualization and post-processing, including MCA vessel-density asymmetry, contrast/phase context, overlays, and MIP views, for trained clinical review; it is not for mobile diagnosis and its vessel-density asymmetry ratio is limited to the MCA region.
CTA visualization and analysis support for reviewing hemispheric vessel-density differences, contrast intensity, estimated phase, and registered overlays; the results support but do not replace trained clinical interpretation.
Visualization and post-processing outputs including registration, MIP views, a colored overlay of the MCA hemisphere with lower vessel density, relative vessel-density asymmetry, contrast-intensity measurements, and estimated phase; results can be sent to PACS or viewed through a hospital-network web interface, while email previews are compressed informational attachments.
The vessel-density asymmetry ratio applies only to the MCA region. Brainomix 360 e-CTA is not intended for mobile diagnostic use. Email previews are compressed and for informational notification only; clinicians must view non-compressed images on a diagnostic viewer and complete appropriate patient evaluation before care-related decisions.
K242123 FDA evidence is a retrospective standalone manufacturer-submitted validation of vessel delineation and parenchyma masking on 308 brain CTA scans; all cases were processed successfully. No independent paper or trial was promoted in this timeboxed review.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
K242123 FDA evidence is a retrospective standalone manufacturer-submitted validation of vessel delineation and parenchyma masking on 308 brain CTA scans; all cases were processed successfully. No independent paper or trial was promoted in this timeboxed review.
DesignRetrospective standalone performance study comparing AI/ML vessel delineation and parenchyma masking with the stated reference process across clinical CTA scans.
Population308 US brain CTA scans: 179 from Boston Medical Centre or referring Massachusetts hospitals and 129 from Mayo Clinic Rochester; scanners included Siemens, GE, Philips, and Canon/Toshiba systems, with demographic, site, scanner, and stenosis stratifications.
Scopeexact submission
Tested versionBrainomix 360 e-CTA configuration described in K242123
Samplen=308
IndependenceSponsor or vendor study
K242123
Manufacturer-submitted FDA evidence; the named clinical sources do not make this an independent investigator study.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-submission FDA recall query returned no native recall record for K242123. This is not a comprehensive safety clearance and does not exclude family, later-version, or adverse-event information.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Brain CT angiography images acquired through DICOM-compliant imaging devices and transferred from a PACS or other DICOM-compliant device.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact submission can receive CTA scans from a PACS through DICOM, send results and images to PACS through DICOM, and expose results through a web interface on a machine within the hospital network and firewall; local routing, worklist, email, viewer, and failure behavior require acceptance testing.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact submission runs on standard off-the-shelf physical or virtual server hardware and is accessed through a hospital network and firewall or LAN connection; the reviewed sources do not establish the current site-specific hosting, storage, retention, availability, or service-level arrangement.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Visualization and post-processing outputs including registration, MIP views, a colored overlay of the MCA hemisphere with lower vessel density, relative vessel-density asymmetry, contrast-intensity measurements, and estimated phase; results can be sent to PACS or viewed through a hospital-network web interface, while email previews are compressed informational attachments.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Visualization and post-processing outputs including registration, MIP views, a colored overlay of the MCA hemisphere with lower vessel density, relative vessel-density asymmetry, contrast-intensity measurements, and estimated phase; results can be sent to PACS or viewed through a hospital-network web interface, while email previews are compressed informational attachments.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact submission runs on standard off-the-shelf physical or virtual server hardware and is accessed through a hospital network and firewall or LAN connection; the reviewed sources do not establish the current site-specific hosting, storage, retention, availability, or service-level arrangement.
The exact submission can receive CTA scans from a PACS through DICOM, send results and images to PACS through DICOM, and expose results through a web interface on a machine within the hospital network and firewall; local routing, worklist, email, viewer, and failure behavior require acceptance testing.
Brainomix's current official FAQ describes ISO 27001, GDPR, and DPA controls for the current Brainomix 360 family; this does not establish certificate scope, expiry, deployed configuration, or exact K243294 security controls.
Product family
Checked 2026-10-25
Obtain current certificate scope, data-processing terms, hosting region, encryption, identity/access, audit, retention, and incident-response evidence for the deployed release.
Monitor CTA transfer and protocol eligibility, MCA-only interpretation of vessel-density asymmetry, image-quality and registration failures, compressed-preview versus diagnostic-viewer use, PACS/web/email delivery, failed or repeated analyses, reader overrides, downtime, updates, complaints, and exact-submission recalls.
Exact FDA submission
Checked 2026-09-07
Buyer acceptance guidance derived from the exact FDA workflow and validation scope; it is not a claimed vendor monitoring service.
Brainomix's current FAQ says Brainomix 360 Stroke results are typically available within 1-2 minutes and delivered via PACS, email, mobile app, or web browser; it supports major scanner and PACS manufacturers through standard DICOM and engineers test connections before go-live. This is family-level context and does not establish exact K242123 latency or configuration.
Brainomix's current FAQ describes a managed appliance on virtualized cloud or physical hardware, with vendor-led installation, scanner/PACS connection, protocol setup, and go-live testing alongside hospital IT; it also describes group training and multilingual manuals for clinical users. Exact K242123 terms and curriculum were not established.
The FDA packet describes DICOM transfer to and from PACS, hospital-network web viewing, and compressed email previews that are not diagnostic; confirm local routing, diagnostic-viewer access, notification policy, and failure recovery during qualification.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-07Last searched
24Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The stored PubMed and ClinicalTrials.gov candidate arrays were screened and were empty. No paper or trial was promoted; empty stored arrays do not establish that no external literature or trials exist. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, stored candidate metadata, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-07 - Exact FDA submission
No public list price or exact contract unit for K242123 was established in the reviewed official sources.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission
Bounded web search on 2026-10-26 (query: "Brainomix 360 reimbursement CPT NTAP"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. No Brainomix page naming coding or payment for this product was found. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not publicly available - checked 2026-09-07 - Exact FDA submission
The FDA indication requires trained professionals; the official FAQ describes family training but does not establish an exact K242123 curriculum or competency assessment.
Authorized purpose: Assists clinician assessment of brain abnormalities and ischemic injury by generating an automated ASPECTS score for known MCA/ICA occlusion cases.
Authorized purpose: Analyzes CT data to display head and neck vasculature and CT perfusion to generate regional blood-flow, blood-volume, mean-transit-time, and capillary-permeability images.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.